Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 127

1.

Deletion Mutations Keep Kinase Inhibitors in the Loop.

Freed DM, Park JH, Radhakrishnan R, Lemmon MA.

Cancer Cell. 2016 Apr 11;29(4):423-5. doi: 10.1016/j.ccell.2016.03.017.

PMID:
27070691
2.

The Dark Side of Cell Signaling: Positive Roles for Negative Regulators.

Lemmon MA, Freed DM, Schlessinger J, Kiyatkin A.

Cell. 2016 Mar 10;164(6):1172-84. doi: 10.1016/j.cell.2016.02.047. Review.

PMID:
26967284
3.

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.

Infarinato NR, Park JH, Krytska K, Ryles HT, Sano R, Szigety KM, Li Y, Zou HY, Lee NV, Smeal T, Lemmon MA, Mossé YP.

Cancer Discov. 2016 Jan;6(1):96-107. doi: 10.1158/2159-8290.CD-15-1056. Epub 2015 Nov 10.

4.

EGFR mutations cause a lethal syndrome of epithelial dysfunction with progeroid features.

Ganetzky R, Finn E, Bagchi A, Zollo O, Conlin L, Deardorff M, Harr M, Simpson MA, McGrath JA, Zackai E, Lemmon MA, Sondheimer N.

Mol Genet Genomic Med. 2015 Sep;3(5):452-8. doi: 10.1002/mgg3.156. Epub 2015 Jun 4.

5.

Ligand regulation of a constitutively dimeric EGF receptor.

Freed DM, Alvarado D, Lemmon MA.

Nat Commun. 2015 Jun 10;6:7380. doi: 10.1038/ncomms8380.

6.

Comparison of Saccharomyces cerevisiae F-BAR domain structures reveals a conserved inositol phosphate binding site.

Moravcevic K, Alvarado D, Schmitz KR, Kenniston JA, Mendrola JM, Ferguson KM, Lemmon MA.

Structure. 2015 Feb 3;23(2):352-63. doi: 10.1016/j.str.2014.12.009. Epub 2015 Jan 22.

7.

ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.

Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H, Laudenslager M, Rappaport EF, Wood AC, McGrady PW, Hogarty MD, London WB, Radhakrishnan R, Lemmon MA, Mossé YP.

Cancer Cell. 2014 Nov 10;26(5):682-94. doi: 10.1016/j.ccell.2014.09.019. Epub 2014 Nov 10.

8.

Putting together structures of epidermal growth factor receptors.

Bessman NJ, Freed DM, Lemmon MA.

Curr Opin Struct Biol. 2014 Dec;29:95-101. doi: 10.1016/j.sbi.2014.10.002. Epub 2014 Oct 24. Review.

9.

Complex relationship between ligand binding and dimerization in the epidermal growth factor receptor.

Bessman NJ, Bagchi A, Ferguson KM, Lemmon MA.

Cell Rep. 2014 Nov 20;9(4):1306-17. doi: 10.1016/j.celrep.2014.10.010. Epub 2014 Nov 6.

10.

TIPE3 is the transfer protein of lipid second messengers that promote cancer.

Fayngerts SA, Wu J, Oxley CL, Liu X, Vourekas A, Cathopoulis T, Wang Z, Cui J, Liu S, Sun H, Lemmon MA, Zhang L, Shi Y, Chen YH.

Cancer Cell. 2014 Oct 13;26(4):465-78. doi: 10.1016/j.ccr.2014.07.025. Epub 2014 Sep 18.

11.

The EGFR family: not so prototypical receptor tyrosine kinases.

Lemmon MA, Schlessinger J, Ferguson KM.

Cold Spring Harb Perspect Biol. 2014 Apr 1;6(4):a020768. doi: 10.1101/cshperspect.a020768. Review.

12.

Mechanism for activation of mutated epidermal growth factor receptors in lung cancer.

Red Brewer M, Yun CH, Lai D, Lemmon MA, Eck MJ, Pao W.

Proc Natl Acad Sci U S A. 2013 Sep 17;110(38):E3595-604. doi: 10.1073/pnas.1220050110. Epub 2013 Sep 9. Erratum in: Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20344.

13.

Receptor tyrosine kinases with intracellular pseudokinase domains.

Mendrola JM, Shi F, Park JH, Lemmon MA.

Biochem Soc Trans. 2013 Aug;41(4):1029-36. doi: 10.1042/BST20130104. Review.

14.

Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain.

Park JH, Liu Y, Lemmon MA, Radhakrishnan R.

Biochem J. 2012 Dec 15;448(3):417-23. doi: 10.1042/BJ20121513.

15.

Assessing the range of kinase autoinhibition mechanisms in the insulin receptor family.

Artim SC, Mendrola JM, Lemmon MA.

Biochem J. 2012 Dec 1;448(2):213-20. doi: 10.1042/BJ20121365.

16.

Occupy EGFR.

Park JH, Lemmon MA.

Cancer Discov. 2012 May;2(5):398-400. doi: 10.1158/2159-8290.CD-12-0144.

17.

Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.

Carpenter EL, Haglund EA, Mace EM, Deng D, Martinez D, Wood AC, Chow AK, Weiser DA, Belcastro LT, Winter C, Bresler SC, Vigny M, Mazot P, Asgharzadeh S, Seeger RC, Zhao H, Guo R, Christensen JG, Orange JS, Pawel BR, Lemmon MA, Mossé YP.

Oncogene. 2012 Nov 15;31(46):4859-67. doi: 10.1038/onc.2011.647. Epub 2012 Jan 23. Erratum in: Oncogene. 2012 Nov 15;31(46):4888. Vigny, M [added]; Mazot, P [added].

18.

Finding the missing links in EGFR.

Bessman NJ, Lemmon MA.

Nat Struct Mol Biol. 2012 Jan 5;19(1):1-3. doi: 10.1038/nsmb.2221. No abstract available.

PMID:
22218287
19.

Conditional peripheral membrane proteins: facing up to limited specificity.

Moravcevic K, Oxley CL, Lemmon MA.

Structure. 2012 Jan 11;20(1):15-27. doi: 10.1016/j.str.2011.11.012. Epub 2011 Dec 21. Review.

20.

Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

Bresler SC, Wood AC, Haglund EA, Courtright J, Belcastro LT, Plegaria JS, Cole K, Toporovskaya Y, Zhao H, Carpenter EL, Christensen JG, Maris JM, Lemmon MA, Mossé YP.

Sci Transl Med. 2011 Nov 9;3(108):108ra114. doi: 10.1126/scitranslmed.3002950.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk